Reg 74(5) compliance filing for quarter ended September 30, 2026

Compliance View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.0%Reaction day

₹32.50

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.2%-0.2% vs market

Pharmaceuticals peers, median of 168sector-0.3%+0.3% vs sector

On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.0+0.2-0.2-0.3+0.3

Next day

-2.5+0.9-3.4-0.3-2.2

-2.9-0.8-2.1-1.2-1.7

-1.5-0.1-1.5-1.0-0.5

-1.5-1.7+0.2-2.6+1.1

-7.8-4.3-3.5-3.8-3.9

-7.4-7.5+0.1-6.4-0.9

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 168Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Goldline Pharmaceutical has submitted the Regulation 74(5) certificate to BSE for the quarter and half year ended September 30, 2026. The Registrar Bigshare Services confirmed the regulation does not apply because all company shares are already held in demat form and no requests for dematerialization or rematerialization were received during the quarter. This is a routine regulatory compliance submission with no material business impact.

Likely market impact

Routine compliance filing with no material impact on shareholders or the stock. All shares are already held in demat form.